AQR Capital Management’s Ultragenyx Pharmaceutical RARE Stock Holding History

AQR Capital Management’s Portfolio RARE Stock Details RARE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$95.9M	Buy	4,578,024 +3,217,527	+236%	+$72.5M	0.04%	536
2025 Q4	$31.3M	Buy	1,360,497 +614,315	+82%	+$20.2M	0.02%	807
2025 Q3	$22.4M	Buy	746,182 +493,849	+196%	+$14.8M	0.01%	821
2025 Q2	$9.17M	Buy	252,333 +160,286	+174%	+$5.78M	0.01%	1000
2025 Q1	$3.31M	Sell	92,047 -188,500	-67%	-$7.84M	﹤0.01%	1333
2024 Q4	$11.8M	Sell	280,547 -763,826	-73%	-$37.9M	0.02%	784
2024 Q3	$57.8M	Buy	1,044,373 +947,273	+976%	+$48.3M	0.08%	330
2024 Q2	$3.99M	Sell	97,100 -154,097	-61%	-$6.58M	0.01%	1118
2024 Q1	$11.7M	Buy	251,197 +80,508	+47%	+$3.8M	0.02%	669
2023 Q4	$8.16M	Buy	+170,689	New	+$6.62M	0.02%	770
2023 Q2	–	Sell	-35,911	Closed	-$1.41M	–	2262
2023 Q1	$1.41M	Buy	35,911 +19,997	+126%	+$858K	﹤0.01%	1404
2022 Q4	$729K	Buy	15,914 +5,692	+56%	+$224K	﹤0.01%	1673
2022 Q3	$423K	Buy	+10,222	New	+$525K	﹤0.01%	1848
2021 Q3	–	Sell	-9,500	Closed	-$906K	–	2311
2021 Q2	$906K	Sell	9,500 -19,284	-67%	-$2.01M	﹤0.01%	1632
2021 Q1	$3.28M	Sell	28,784 -9,234	-24%	-$1.26M	0.01%	953
2020 Q4	$5.26M	Buy	38,018 +8,959	+31%	+$1.06M	0.01%	768
2020 Q3	$2.39M	Buy	29,059 +1,576	+6%	+$131K	﹤0.01%	1034
2020 Q2	$2.15M	Buy	27,483 +3,836	+16%	+$254K	﹤0.01%	1128
2020 Q1	$1.05M	Buy	23,647 +18,220	+336%	+$946K	﹤0.01%	1326
2019 Q4	$232K	Buy	+5,427	New	+$224K	﹤0.01%	1972
2019 Q3	–	Sell	-7,283	Closed	-$462K	–	2152
2019 Q2	$462K	Buy	+7,283	New	+$464K	﹤0.01%	1757
2019 Q1	–	Sell	-7,858	Closed	-$342K	–	2211
2018 Q4	$342K	Buy	7,858 +976	+14%	+$53.3K	﹤0.01%	1922
2018 Q3	$525K	Buy	+6,882	New	+$560K	﹤0.01%	1942
2016 Q3	–	Sell	-6,419	Closed	-$314K	–	2284
2016 Q2	$314K	Sell	6,419 -11,924	-65%	-$771K	﹤0.01%	2002
2016 Q1	$1.16M	Sell	18,343 -14,750	-45%	-$965K	﹤0.01%	1516
2015 Q4	$3.71M	Sell	33,093 -1,684	-5%	-$168K	0.01%	1004
2015 Q3	$3.35M	Buy	34,777 +12,185	+54%	+$1.4M	0.01%	927
2015 Q2	$2.31M	Buy	+22,592	New	+$1.75M	﹤0.01%	1124

Other funds holding RARE

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

AQR Capital Management's RARE Position: Q1 2026 in Review

AQR Capital Management increased its Ultragenyx Pharmaceutical (RARE) stake by 236% in Q1 2026, buying an estimated $72.5M and bringing the position to 4,578,024 shares worth $95.9M. The position accounts for 0.04% of the portfolio, ranked #536.

AQR Capital Management first reported a position in RARE in Q2 2015 and has held it in 28 quarters since. 295 funds tracked by Wall St. Rank hold RARE as of Q1 2026.

AQR Capital Management held 4,578,024 shares of Ultragenyx Pharmaceutical worth $95.9M as of Q1 2026.
AQR Capital Management bought 3,217,527 Ultragenyx Pharmaceutical shares in Q1 2026, an estimated $72.5M.
Ultragenyx Pharmaceutical made up 0.04% of AQR Capital Management's portfolio in Q1 2026, its #536 holding.
AQR Capital Management first reported a position in Ultragenyx Pharmaceutical in Q2 2015 and has held it in 28 quarters since.
295 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q1 2026.

Based on AQR Capital Management's 13F filing for Q1 2026, filed 15 May 2026.